Zika Seen as $200M - $400M Annual Opportunity for Intrexon (XON); Stifel Affirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Zika Stock Intrexon (XON) Gains 5% Early
February 3, 2016 7:51 AM ESTZika stock Intrexon (NYSE: XON) is seeing early upside. Shares are up 5%.
Intrexon (XON) Adds to Gains as Zika Opportunity Laid Out
February 1, 2016 11:43 AM ESTIntrexon (NYSE: XON) has been pushing higher all day on continued Zika scares. Shares are up 10.3%.
This morning, Stifel analyst Thomas Shrader said he sees the Zika virus as a $200 to $400 million annual opportunity for Intrexon, even with a cautious adoption ramp.
... MoreIntrexon (XON) CEO expected to be on CNBC tomorrow to discuss Zika
January 28, 2016 3:18 PM ESTIntrexon (NYSE: XON) CEO expected to be on CNBC tomorrow to discuss Zika
... MoreGriffin Securities Sees More Countries Approving Intrexon's (XON) OX513A Amid Zika Pandemic
January 28, 2016 3:15 PM ESTGriffin Securities reaffirms Intrexon (NYSE: XON) with a Buy rating and $65 price target, saying the company's Oxitec subsidiary has an answer for the Zika pandemic.
Analyst Keith A. Markey, commented, The Companys genetically modified, male Aedes aegypti mosquito (OX513A) has... More
Zika Pandemic May Push U.S. to Approve Intrexon's (XON) OX513A - Griffin Securities
January 28, 2016 3:15 PM ESTGriffin Securities analyst Keith Markey reiterated a Buy rating and $65 price target on Intrexon (NYSE: XON), citing the company's opportunity related to the Zika pandemic, which has been linked to serious brain damage in infants.
Markey notes the company's Oxitec subsidiary has an environmentally friendly answer to the Zika pandemic, which is largely transmitted via the Aedes aegypti and Aedes Albopictus mosquitoes, which also carry the dengue fever virus.
"The Companys genetically modified,... More
Intrexon (XON), Inovio Pharma (INO) Moving Back to Highs on Zika Outbreak
January 28, 2016 11:08 AM ESTAfter consolidating this morning's move higher, Intrexon (NYSE: XON) and Inovio Pharma (NASDAQ: INO) are moving to the highs following the continued Zika outbreak which the WHO said is "spreading explosively."
... More